news-events

Satya is attending the BIO at Boston during June 3-6, 2023. Please also visit the India Pavilion with an exhibit of Satya’s poster and pipeline

Please set up a meeting with CSN at murthycsn@satyarx.com

Navnath Karche, PhD, a Medicinal Chemist with over 18 years of experience across multiple discovery programs in Oncology, Metabolic Disorders, and CNS therapeutic areas. Navnath previously worked at Dai-Ichi and Lupin, after his PhD from Pune University and post-doc from Rouen, France. Ganesh Gudade, with over 20 years of MedChem experience at Lupin, Glenmark and

Srikant Viswanadha, an accomplished industry leader, has joined Satya as its CSO. Srikant has over 19 years’ pharmaceutical experience in reputed companies, and has been involved in the discovery and early clinical development of multiple programs. He was last the CSO at Incozen/ Rhizen. Manoj Pothuganti has also joined Satya as a Program Lead and

Satya is attending the ASCO Annual Meeting between June 3-6, 2022 at Chicago, IL.

Satya is expanding its lab infrastructure and team size at its facilities in Hyderabad, India to add additional discovery programs to the pipeline. Upon completion, the lab size would double and the company can run up to six discovery programs in parallel.

Poster 6368: “Discovery of potent, orally bioavailable, SOS1 inhibitors for KRAS-driven tumors” Abstract   KRAS is an oncogene implicated in a wide variety of tumors (~21% of solid tumors harbor KRAS mutations). KRAS interaction with Guanidine Exchange Factors (GEFs) is crucial for its activation, with SOS1 being the predominant GEF. SOS1 inhibition is thus expected

Poster #LBA041: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer, October 7-10, 2021 The DNA damage response (DDR) is a complex cellular network that acts as a cell defense mechanism and exerts signal for repair of DNA lesions. It repairs different types of DNA damage such as single-strand (ssDNA) breaks, DNA inter-strand crosslinks and